Institutional members access full text with Ovid®

Share this article on:

New Treatment Option: 223Ra Chloride, the First Approved Unsealed α-Emitting Radiopharmaceutical

Colletti, Patrick M. MD

doi: 10.1097/RLU.0b013e3182a2dd53
Interesting Images

Abstract: A 66-year-old man with prostate cancer presented with intractable pain associated with multifocal bone metastases. After receiving 180 µCi (1.35 µCi/kg) of 223Ra chloride, radiation survey measured 0.2 mR/h at 1 m, and the patient was discharged to home. He will return monthly for the next 5 months for repeat 223Ra chloride administrations. 223Ra chloride is the first Food and Drug Administration–approved unsealed α-emitting radiopharmaceutical.

From the University of Southern California, Los Angeles, CA.

Received for publication June 28, 2013; revision accepted June 28, 2013.

Conflicts of interest and sources of funding: none declared.

Reprints: Patrick M. Colletti, MD, University of Southern California, LAC+USC Medical Center, 1200 N State St, Los Angeles, CA 90033. E-mail: colletti@usc.edu.

© 2013 by Lippincott Williams & Wilkins